Gemcitabine and Cisplatin (Gem-Cis) With Erlotinib (Tarceva) in Hepatocellular Carcinoma (HCC) and Biliary Tree Cancer (BTC) (Intra- and Extra-hepatic Cholangiocarcinoma, Bile Duct Cancer, Adenocarcinoma of the Ampulla of Vater and Gallbladder Carcinoma)
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2016
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary) ; Cisplatin
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms Gem-ox
- 13 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 13 Jul 2015 Status changed from active,no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 05 Mar 2013 Planned number of patients changed from 41 to 82 as reported by ClinicalTrials.gov.